PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES

被引：0
|
作者：
Yuki, S. [1 ]
Shitara, K. [2 ]
Yoshida, M. [3 ]
Takahari, D. [2 ]
Utsunomiya, S. [4 ]
Yokota, T. [2 ]
Sato, Y. [2 ]
Tajika, M. [2 ]
Muro, K. [2 ]
机构：
[1] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[3] Osaka Med Coll, Takatsuki, Osaka 569, Japan
[4] Nagoya Kyouritsu Hosp, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [31] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [32] Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
    Shitara, Kohei
    Yamazaki, Kentaro
    Uetake, Hiroyuki
    Kato, Takeshi
    Oki, Eiji
    Yamanaka, Takeharu
    Ohashl, Yasuo
    Yoshino, Takayukl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
    ELez, E.
    Kocakova, I.
    Hoehler, T.
    Martens, U. M.
    Bokemeyer, C.
    Van Cutsem, E.
    Melichar, B.
    Smakal, M.
    Csoszi, T.
    Topuzov, E.
    Orlova, R.
    Tjulandin, S.
    Rivera, F.
    Straub, J.
    Bruns, R.
    Quaratino, S.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 132 - 140
  • [34] Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer
    Osumi, H.
    Shinozaki, E.
    Suenaga, M.
    Matsusaka, S.
    Nakayama, I.
    Wakatsuki, T.
    Ogura, M.
    Ozaka, M.
    Takashi, I.
    Takahari, D.
    Chin, K.
    Mizunuma, N.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2016, 27 : 16 - 16
  • [35] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [36] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [37] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer: CIRIS study
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
  • [39] Panitumumab or cetuximab combined with irinotecan in patients with KRAS wild-type metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
    Ikezawa, Nobuaki
    Iwasa, Satoru
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko T.
    Kato, Ken
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [40] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345